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Abstract
Treatment of chronic hepatitis C with interferon alpha
(IFN-·) is relatively contraindicated in patients with psy-
chiatric disorders because of possible severe psychiatric
side effects. We report on a case of a female patient with
a chronic schizoaffective psychosis, who was treated for
3 months with 3 ! 3 mio IE IFN-· s.c./week because of a
chronic hepatitis C (genotype 1b). Psychosis was stable
with flupentixol monotherapy. After 2 months, she de-
veloped a severe depressive syndrome which lead to
suicidal ideation. Until this time, she was without any
antidepressive medication. Depressive symptoms disap-
peared after interferon therapy was stopped. Under pro-
phylactic treatment with low-dose trimipramine (50 mg)
or nefazodone (200 mg/day) therapy with IFN-· 3 !
3 mio IE/week was re-established after several months
and again 2 years later adding ribavirin 1200 mg/day, a
virustaticum. In contrast to the symptoms during mono-
therapy with IFN-·, during the time of both combination
treatments, no psychiatric side effects occurred. While
for ribavirin antidepressant effects are not known, we
suppose that antidepressants may prevent changes
in serotonergic or noradrenergic neurotransmission
caused by IFN-·.
Copyright © 2000 S. Karger AG, Basel
Introduction
Interferon-alpha (IFN-·) is an important part of the
natural immune system with antiviral, antitumor and
immunoregulatory properties. Recently there has been an
extensive therapeutic use of interferons in viral infection
disorders, including hepatitis B and C, neoplastic disor-
ders, myeloproliferative and rheumatic disorders [1]. The
treatment duration differs between months and years.
Besides several possible internal complications, psychiat-
ric side effects like affective, psychotic or delirious syn-
dromes associated with IFN-· therapy often limit the
otherwise effective immunotherapy [2–4]. Worldwide,
100 million people are infected with the hepatitis C virus
and 70% of those develop a chronic hepatitis C. Most of
them need treatment to avoid complications such as liver
cirrhosis, which occurs in 15–20% [5]. The only effective
treatment has been IFN-· so far. But in psychiatric
patients, treatment with IFN-· is still considered as con-
traindicated because of the hypothetical increased risk for
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Fig. 1. Psychiatric rating scales during treat-
ment with IFN-· and ribavirin. GAF =
Global Assessment of Functioning Scale;
SDS = Self-Rating Depression Scale;
MADRS = Montgomery-Asberg Depression
Scale; BPRS = Brief Psychiatric Rating
Scale; STAIX1 = State-Trait-Anxiety Inven-
tory.
the development of depressive and suicidal syndromes
[6]. Antidepressants were shown to be sometimes helpful
in the treatment of depressive syndromes associated with
IFN-· [7] and may save patients from the necessary dis-
continuation of therapy. But it is not yet known if antide-
pressants may have a protective effect and if retreatment
with IFN-· is possible in psychiatric patients who devel-
oped severe depressive side effects during earlier IFN-·
treatment. The presented prospective and clinically ex-
tensively characterized case of a ‘high-risk’ patient with
schizoaffective disorder gives evidence for the efficacy of
antidepressants even in low dose in the prevention of
IFN-·-associated depressive syndromes.
Case Report
The 40-year-old female patient was treated with IFN-· because of
a chronic hepatitis C. Hepatitis C was diagnosed in 1996 with geno-
type 1b, which is known to be associated with a bad prognosis and
bad response to monotherapeutic treatment with IFN-·. After a sui-
cide attempt in 1986, the patient was diagnosed as having schizoaf-
fective disorder and has been treated continuously since 1995 with
flupentixol monotherapy, occasionally in combination with trimi-
pramine or amitriptyline up to 75 mg/day. This led to an ameliora-
tion of psychotic symptoms for more than 5 years, whereas depres-
sive symptoms intermittently reappeared.
In 1996, monotherapeutic treatment of hepatitis C with IFN-·
3 ! 3 mio IE/week was initiated under continuous psychiatric care.
At this time, the patient was under flupentixol monotherapy and
without psychotic or depressive symptoms. After 2 months of IFN-·
treatment, she developed a severe depressive syndrome with de-
pressed mood, agitation, sleeping disturbance, anxiety and suicidal
ideation. IFN-· was stopped, and the patient was consecutively put
on trimipramine (75 mg/day) and later amitriptyline (50 mg/day).
One week after discontinuation of IFN-·, proneness to suicide was
diminished, followed by the amelioration of the other depressive
symptoms 2 weeks later.
In 1997, a combination therapy with ribavirin (1,000 mg/day)
and IFN-· 3 ! 3 mio IE/week was started while on psychiatric treat-
ment with flupentixol (1 ml 2% every 3 weeks) and trimipramine
(50 mg/day). Especially in patients with hepatitis virus genotype 1,
response to combination treatment is better compared to monothera-
py. Neither psychiatric syndromes nor other severe side effects were
noticed by the psychiatrist or by the patient herself. Treatment was
stopped after 4 months because the PCR for hepatitis C virus was
still positive, whereas liver enzymes were normalized (partial re-
sponse).
In 1998, the patient wished to start again on a combination treat-
ment with ribavirin (1,000 mg/day) and IFN-· 3 ! 3 mio IE/week
for 6 months. A special study design for treatment of psychiatric
patients with chronic hepatitis C was applied. She was treated contin-
uously with flupentixol and nefazodone in a low dose (100 mg/day).
Under this medication, no depressive symptoms were noticed.
Again, she did not complain about any severe psychiatric side effects
during combination treatment of hepatitis C. Prospective psychiatric
ratings like the BPRS (Brief Psychiatric Rating Scale) or the Mont-
gomery-Asberg Depression Scale, as well as self-rating instruments
for anxiety and depressive symptoms (STAIX1, SDS) showed no rel-
evant negative changes (fig. 1). However, the PCR for hepatitis C
virus detection was still positive after 6 months, and the patient was
considered as not responding to this treatment.
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Discussion
Comparing combination treatment with IFN-· mono-
therapy, the patient experienced aggressive feelings, anxi-
ety, lack of drive, irritability, depressive mood, sleeping
disturbance, loss of interests, ambivalence, disturbance of
concentration, rumination, suicidal thoughts, mood insta-
bility and inner restlessness only during monotherapy.
Only drowsiness was described as noteworthy during
combination treatment. The patient was not in a depres-
sive mood before the IFN-· treatments. In contrast to the
monotherapeutic regime with IFN-· in 1996, the patient
was under continuous antidepressive treatment during
both combination therapies. Serotonergic-acting antide-
pressants have recently been shown to be effective in pre-
venting psychiatric side effects with high-dose interferon
treatment for malignant melanoma given before starting
the IFN-· treatment [8]. Accordingly, antidepressant
medication with trimipramine or nefazodone possibly
prevented depressive symptoms in our patient. However,
the therapeutic dose recommended for nefazodone is
400–600 mg/day. Our patient only received a low-dose
treatment for both antidepressants used. Interestingly,
besides depressive symptoms, most patients develop irri-
tability or aggression under treatment with IFN-·. Impul-
sive, aggressive behavior and depression are thought to be
connected to serotonergic dysfunction. In fact, cytokines
like IL-1 and IL-6, which are influenced by IFN-·, are
known to alter the cerebral metabolism of noradrenaline
and serotonin [9]. IFN-· affects low-affinity 5-HT1A
receptor sites in rats [10] and increases levels of serotonin
transporter mRNA [11].
Another possibility could be a better tolerability of the
combination therapy with IFN-· and ribavirin. Even if
large clinical studies suggest that the prevalence of severe
psychiatric side effects with suicidal ideation is similar for
the patients treated with IFN-· 2b and ribavirin com-
pared to monotherapy with IFN-· 2b (3.6 vs. 2.2 %), they
were done without valid psychiatric ratings [12, 13]. If it
holds true that adding ribavirin reduces psychiatric side
effects of IFN-· in selected patients, the underlying mech-
anism remains still unclear.
In conclusion, pretreatment with low-dose antidepres-
sants may be effective in preventing depression as a sero-
tonergic side effect of IFN-· treatment. Further studies to
evaluate the psychiatric tolerability of the new combina-
tion treatment with IFN-· and ribavirin for chronic hepa-
titis C are needed. To our knowledge, there is no justifi-
able reason to exclude psychiatric patients from effective
treatment for chronic hepatitis C, even in cases of earlier
side effects [14].
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